| A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study A Banerjee, RI Jakacki, A Onar-Thomas, S Wu, T Nicolaides, ... Neuro-oncology 19 (8), 1135-1144, 2017 | 312 | 2017 |
| Crenolanib is active against models of drug-resistant FLT3-ITD− positive acute myeloid leukemia EI Zimmerman, DC Turner, J Buaboonnam, S Hu, S Orwick, MS Roberts, ... Blood, The Journal of the American Society of Hematology 122 (22), 3607-3615, 2013 | 213 | 2013 |
| Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance DC Turner, AG Kondic, KM Anderson, AG Robinson, EB Garon, JW Riess, ... Clinical Cancer Research 24 (23), 5841-5849, 2018 | 182 | 2018 |
| Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer M Chatterjee, DC Turner, E Felip, H Lena, F Cappuzzo, L Horn, EB Garon, ... Annals of Oncology 27 (7), 1291-1298, 2016 | 158 | 2016 |
| Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma M Morfouace, A Shelat, M Jacus, BB Freeman, D Turner, S Robinson, ... Cancer cell 25 (4), 516-529, 2014 | 158 | 2014 |
| Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response H Li, J Yu, C Liu, J Liu, S Subramaniam, H Zhao, GM Blumenthal, ... Journal of pharmacokinetics and pharmacodynamics 44, 403-414, 2017 | 119 | 2017 |
| Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells AE Vilgelm, JS Pawlikowski, Y Liu, OE Hawkins, TA Davis, J Smith, ... Cancer research 75 (1), 181-193, 2015 | 89 | 2015 |
| Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab‐treated advanced melanoma MS Chatterjee, J Elassaiss‐Schaap, A Lindauer, DC Turner, A Sostelly, ... CPT: pharmacometrics & systems pharmacology 6 (1), 29-39, 2017 | 84 | 2017 |
| Analytics: The real-world use of big data in financial services D Turner, M Schroeck, R Shockley IBM Global Business Services 27 (16), 5, 2013 | 73 | 2013 |
| Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors F Navid, SD Baker, MB McCarville, CF Stewart, CA Billups, J Wu, ... Clinical Cancer Research 19 (1), 236-246, 2013 | 73 | 2013 |
| An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) M DeWire, M Fouladi, DC Turner, C Wetmore, C Hawkins, C Jacobs, ... Journal of neuro-oncology 123, 85-91, 2015 | 68 | 2015 |
| Near-infrared image-guided delivery and controlled release using optimized thermosensitive liposomes DC Turner, D Moshkelani, CS Shemesh, D Luc, H Zhang Pharmaceutical research 29, 2092-2103, 2012 | 50 | 2012 |
| Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing DC Turner, F Navid, NC Daw, S Mao, J Wu, VM Santana, M Neel, B Rao, ... Clinical cancer research 20 (10), 2783-2792, 2014 | 47 | 2014 |
| Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group TJ MacDonald, G Vezina, CF Stewart, D Turner, CR Pierson, L Chen, ... Neuro-oncology 15 (10), 1438-1444, 2013 | 44 | 2013 |
| BrainIAK: the brain imaging analysis kit M Kumar, MJ Anderson, JW Antony, C Baldassano, PP Brooks, MB Cai, ... Aperture neuro 1 (4), 2021 | 40 | 2021 |
| Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma KD Wright, VM Daryani, DC Turner, A Onar-Thomas, N Boulos, BA Orr, ... Neuro-oncology 17 (12), 1620-1627, 2015 | 39 | 2015 |
| Immunogenicity of pembrolizumab in patients with advanced tumors MJH van Vugt, JA Stone, RH De Greef, ES Snyder, L Lipka, DC Turner, ... Journal for ImmunoTherapy of Cancer 7, 1-8, 2019 | 37 | 2019 |
| Pembrolizumab: role of modeling and simulation in bringing a novel immunotherapy to patients with melanoma R De Greef, J Elassaiss‐Schaap, M Chatterjee, DC Turner, M Ahamadi, ... CPT: Pharmacometrics & Systems Pharmacology 6 (1), 5-7, 2017 | 32 | 2017 |
| Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization–tandem mass spectrometry (LC-ESI–MS/MS) MS Roberts, DC Turner, A Broniscer, CF Stewart Journal of Chromatography B 960, 151-157, 2014 | 32 | 2014 |
| Molecular dynamics simulations of glycocholate− oleic acid mixed micelle assembly DC Turner, F Yin, JT Kindt, H Zhang Langmuir 26 (7), 4687-4692, 2010 | 32 | 2010 |
